HeimADAPY • OTCMKTS
add
Adaptimmune Therapeutics PLC - ADR
Við síðustu lokun
0,041 $
Dagbil
0,035 $ - 0,042 $
Árabil
0,020 $ - 0,86 $
Markaðsvirði
9,58 m. USD
Meðalmagn
95,52 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
OTCMKTS
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 13,68 m. | -89,33% |
Rekstrarkostnaður | 18,48 m. | -3,13% |
Nettótekjur | -30,34 m. | -143,64% |
Hagnaðarhlutfall | -221,83 | -509,13% |
Hagnaður á hvern hlut | -0,12 | -150,00% |
EBITDA | -27,78 m. | -138,88% |
Virkt skatthlutfall | -2,06% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 26,06 m. | -87,87% |
Heildareignir | 130,63 m. | -59,39% |
Heildarskuldir | 201,59 m. | -10,57% |
Eigið fé alls | -70,96 m. | — |
Útistandandi hlutabréf | 265,05 m. | — |
Eiginfjárgengi | -0,15 | — |
Arðsemi eigna | -52,45% | — |
Ávöxtun eigin fjár | 1.376,60% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -30,34 m. | -143,64% |
Handbært fé frá rekstri | -34,78 m. | -173,38% |
Reiðufé frá fjárfestingum | 18,49 m. | 2.588,56% |
Reiðufé frá fjármögnun | 1,65 m. | -93,25% |
Breyting á handbæru fé | -15,23 m. | -121,40% |
Frjálst peningaflæði | -23,84 m. | -135,30% |
Um
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
Framkvæmdastjóri
Stofnsett
2008
Vefsvæði
Starfsfólk
506
